Involving a bifurcation site, restenotic lesions (including in-stent restenosis), two-vessel disease (a maximum of 2 lesions located in 2 different epicardial vessels), long lesions (≥ 25 mm). 

Methods: The primary endpoint of the study is the Target Lesion Revascularization (TLR) rate at 180 days after stent implantation. Secondary endpoints are Target Vessel Failure (TVF), Major Adverse Cardiac Events (MACE) at 30 days and 180 days, MACE at 1-year, 2-years and 3-years in a subset of 500 patients, device success, procedure success and resource utilization.

Results: As of abstract submission: data about 1021 patients enrolled at 87 investigational sites is available for analysis, for a total of 1,435 lesions treated. Amongst, 374 (34%) were restenotic lesions.

Conclusions: The patient recruitment in the DELIVER II study was completed on 9th of September 2002. Thirty-day safety results from the restenotic lesions subgroup will be available for presentation and will be compared with the outcome of other lesion subgroups. Multivariate analysis combining restenosis with other complicating factors will be presented as well.

* Manufactured by Cook Incorporated. DELIVER II is conducted by Guidant Corporation on behalf of Cook Incorporated.